Raubling, 19 October 2023 – Axplora, a leading partner to Pharma and Biotech companies for complex APIs, is delighted to welcome Dr. Stephan Haitz as President of the Novasep CDMO Business Unit and member of the company’s Executive Committee, effective November 1st, 2023. Stephan will take over from Jean Bléhaut, who leaves the company after a career spanning more than 25 years.
Stephan Haitz has a 20+ years’ business career in the pharmaceutical industry where he held various management positions within global CDMOs such as Solvias, Lonza and Cambrex. He holds a PhD and Master in organic chemistry and a Bachelor of Science in economics. Most recently, Stephan worked as President Drug Substance CDMO Commercial at Cambrex.
“I’d like to warmly thank Jean for many years of service at Novasep and wish him the best for the future. I’m now looking forward to entrusting the reins of the BU to Stephan to further consolidate the company’s position as a leader in the CDMO market, while bringing new energy and ideas,” stated Dr. Sylke Hassel, CEO at Axplora.“Stephan will work closely with the Executive Committee and particularly with Dr. Pere Paton, our Chief Operations Officer.”
“I am thrilled to join Axplora at a time when bringing drugs to patients globally is more important than ever. Thanks to Axplora’s wide range of technical capabilities and manufacturing excellence, the Novasep CDMO BU is well suited to support customers with developing and delivering innovative API´s and intermediates”, said Dr. Stephan Haitz. “I am excited to be a part of such an experienced Management team and working closely with Pere to continue building the organization and driving its growth as a leading CDMO.”
“I look forward to working closely with Stephan to develop and implement our operations strategy and vision within the CDMO BU, strengthening our manufacturing network to serve our clients and their patients,” asserts Dr. Pere Paton.
About Axplora
Coming from the merger between Farmabios, Novasep and PharmaZell, Axplora is the preferred API manufacturing partner to the world’s leading patient-centric pharmaceutical and biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. Axplora offers CDMO solutions to innovators for their small molecule and biomolecular active pharmaceutical ingredients, as well as products that address respiratory, inflammatory and liver diseases. Axplora is dedicated to serving pharmaceutical companies to make critical medicines faster, reliably, and to sustainably benefitting patients worldwide. Explore more: axplora.com
Press contact
Justine Reynaud
+33 (0)7 60 93 45 80
Latest news
Press Release
September 29, 2026
Axplora launching “Axotecan” to strengthen Global ADC supply
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with validation batches targeted by the end of 2026 and GMP supply planned for late 2027 Cross-business collaboration combines Farmabios’ HPAPI expertise with Novasep CDMO’s integrated ADC capabilities September 29th, 2026 – Axplora, a global manufacturing […]
News
September 25, 2026
Axplora celebrates 60 years of innovation at Chasse-sur-Rhône
More than 300 employees, family members and guests joined the anniversary celebration on Saturday 19 September. Event honors six decades of expertise and the site’s continuing commitment to reliable, responsible manufacturing for customers and patients September 25, 2026 – Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has marked 60 […]
News
August 05, 2026
Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network
Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. July 2026 – Axplora, a […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.